CD38 as Surrogate Marker for HIV Infection in Antiretroviral Naive and Antiretroviral Experienced Patients in Kenya

Measurements of cluster of differentiation (CD) 4 (CD4) absolute counts and viral load are the two common tools used to monitor disease progression in HIV-1-infected patients on drug therapy. However, there are certain limitations in the use of these tools. Although patients on highly active antiretroviral treatment (HAART) will often exhibit suppressed viral load within the first three weeks of treatment, this is commonly not necessarily accompanied by rapid changes in absolute CD4 counts, thus rendering measurement of levels of CD4 cells unreliable indicators of efficacy of the anti-retroviral treatment at the early stages of intervention.

CD38 Antibody binding capacity
CD38 Antibody binding capacity

Currently, only viral load determination offers a reliable prognostic indicator for antiretroviral (ARV) treatment. However, the cost of estimating viral load is prohibitive, making it difficult for adoption as a routine test. There is need therefore to identify other markers whose levels change rapidly following ARV treatment. Previous studies conducted in Ivory Coast on HIV-1 indicate that CD8+/CD38+ activation molecule can be a sensitive and independent marker.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s